Radiopharm Theranostics Limited (RADX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Sep 18, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RADX SEC filings page.
Radiopharm Theranostics Limited (RADX) reported $3.6M in revenue for fiscal year 2025, up 1114.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expanded sharply, but the business still relies on external funding because operations consume nearly as much cash as accounting losses.
In FY2025, revenue reached$3.6M while operating cash flow was-$36.6M , so reported commercial activity remained tiny relative to the cash required to run the business. Accounts receivable rose from$987K in FY2024 to$10.4M in FY2025 as operating cash flow worsened, indicating that more reported sales had not yet converted into cash.
The balance sheet strengthened through financing rather than operations: total equity increased from
Accounting losses and cash consumption moved together, limiting the benefit of noncash accounting items. Net loss narrowed from
Financial Health Signals
Radiopharm Theranostics Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Radiopharm Theranostics Limited passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, both operating efficiency signals pass.
Radiopharm Theranostics Limited reported a net loss of $38.3M while operations used $36.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Radiopharm Theranostics Limited held $29.1M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
RADX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
RADX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'2410-K |
|---|---|---|
| Total Assets | $86.5M+20.1% | $72.0M |
| Current Assets | $39.9M+74.4% | $22.8M |
| Cash & Equivalents | $29.1M+56.8% | $18.6M |
| Accounts Receivable | $10.4M+953.3% | $987K |
| Total Liabilities | $43.6M-2.4% | $44.7M |
| Current Liabilities | $14.9M-15.0% | $17.6M |
| Non-Current Liabilities | $28.7M+5.8% | $27.1M |
| Total Equity | $42.9M+56.7% | $27.4M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt, Retained Earnings.
RADX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
RADX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Radiopharm Theranostics Limited RADX | FY2025 | $3.6M | -$38.3M | N/A | $15.8M | — |
| PLUS THERAPEUTICS, Inc. PSTV | FY2025 | $5.2M | -$22.4M | N/A | $26.6M | 32/100 |
| Tempest Therapeutics, Inc. TPST | FY2025 | N/A | -$26.3M | N/A | $10.7M | — |
| Lunai Bioworks Inc. RENB | FY2025 | N/A | N/A | N/A | $32.9M | — |
| Barinthus Biotherapeutics plc American BRNS | FY2025 | $0 | -$66.4M | N/A | $30.2M | — |
| Acrivon Therapeutics, Inc. ACRV | FY2025 | N/A | -$77.9M | N/A | $73.7M | — |
Where Radiopharm Theranostics Limited Ranks
Frequently Asked Questions
What is Radiopharm Theranostics Limited's annual revenue?
Radiopharm Theranostics Limited (RADX) reported $3.6M in total revenue for fiscal year 2025. This represents a 1114.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Radiopharm Theranostics Limited's revenue growing?
Radiopharm Theranostics Limited (RADX) revenue grew by 1114.3% year-over-year, from $299K to $3.6M in fiscal year 2025.
Is Radiopharm Theranostics Limited profitable?
No, Radiopharm Theranostics Limited (RADX) reported a net income of -$38.3M in fiscal year 2025.
What is Radiopharm Theranostics Limited's return on equity (ROE)?
Radiopharm Theranostics Limited (RADX) has a return on equity of -89.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Radiopharm Theranostics Limited's operating cash flow?
Radiopharm Theranostics Limited (RADX) recorded an outflow of $36.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Radiopharm Theranostics Limited's total assets?
Radiopharm Theranostics Limited (RADX) had $86.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Radiopharm Theranostics Limited's current ratio?
Radiopharm Theranostics Limited (RADX) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.
What is Radiopharm Theranostics Limited's debt-to-equity ratio?
Radiopharm Theranostics Limited (RADX) had a debt-to-equity ratio of 1.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Radiopharm Theranostics Limited's return on assets (ROA)?
Radiopharm Theranostics Limited (RADX) had a return on assets of -44.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Radiopharm Theranostics Limited's P/E ratio?
Radiopharm Theranostics Limited (RADX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $15.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Radiopharm Theranostics Limited's price-to-sales ratio?
Radiopharm Theranostics Limited (RADX) trades at 4.3x sales, its market capitalization divided by revenue of $3.6M revenue, FY2025. The market capitalization is $15.8M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Radiopharm Theranostics Limited's Piotroski F-Score?
Radiopharm Theranostics Limited (RADX) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Radiopharm Theranostics Limited's earnings high quality?
Radiopharm Theranostics Limited (RADX) reported a net loss of $38.3M while operations used $36.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.